Day: September 8, 2020

Ares Genetics nominated for the 40th Austrian Innovation Award by Federal Ministry for Digital and Economic AffairsARESupa – Universal Pathogenome Assay nominated by expert jury for Austria’s most distinguished innovation awardVIENNA, Austria, and GAITHERSBURG, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) has been nominated for the 40th Austrian Innovation Award (Ref. 1).Ares Genetics has been selected by an expert jury as one of six finalists for its artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic susceptibility test (AST) marketed under the brand name ARESupa – Universal Pathogenome Assay. The Austrian Innovation Award is awarded by the Federal Ministry for Digital...

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE:BBM) (OTCQB: BBRRF) (FRA: 1OA), (the “Company” or “Blueberries“), a Latin American, licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that Camilo Villalba, Co-founder & Chief Executive Office, will present live at VirtualInvestorConferences.com on September 10th.  This will be a live, interactive online event where investors are invited to ask Mr. Villalba questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.Learn more about the event at www.virtualinvestorconferences.com.Recent...

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that enrollment and dosing in its Phase 1/2 clinical trial for MRT5005 in cystic fibrosis (CF) has resumed, with multiple clinical sites being open for enrollment. In March 2020, the Company had announced a pause to enrollment and dosing in the clinical trial in response to the COVID-19 pandemic. The Company plans to provide updated timing on the expected interim data readout of the additional single-ascending dose (SAD) group and the multiple-ascending dose (MAD) portion of the clinical trial at a later date.“We are pleased that enrollment and dosing in the...

Data highlights socio-demographic and clinical disparities to help raise awareness of health inequities and inform future treatment planningReal-world data from MS PATHS identifies clinically relevant benchmarks to predict employment status among people with multiple sclerosis (MS)Biogen is developing digital tools and technologies, such as CogEval® and Konectom™, to facilitate more personalized decisions in MS care with the goal of improving outcomes  CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced findings from two large, real-world studies that provide insight into the clinical and health disparities that exist for people living with multiple sclerosis (MS). These data, from MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) and the North American Registry...

REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming 2nd Annual RAS-Targeted Drug Development Conference being held virtually September 14-16, 2020. Steve Kelsey, M.D., president, research and development, and Jan Smith, Ph.D., senior vice president, biology, will be featured speakers during the digital event.Details of Revolution Medicines’ participation in the 2nd Annual RAS-Targeted Drug Development Conference are as follows:Additional information on the 2nd Annual RAS-Targeted Drug Development Conference is available through the conference website at https://ras-drugdevelopment.com/About...

VANCOUVER, Sept. 08, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) is pleased to announce that it has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for BetterLife and to broaden the Company’s reach within the investment community.Hybrid has agreed to comply with all applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”) in providing the services.“We are happy to be working with Hybrid to help increase our investor awareness in Canada” said Dr. Ahmad Doroudian, CEO of BetterLife. “BetterLife has ambitious plans and a bright future. As we move forward with our pipeline of treatments, in particular...

Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritisWell-tolerated with comparable safety profile to intravenous ertapenemSpero intends to complete NDA submission for U.S. regulatory approval of tebipenem HBr in the second quarter of 2021Management to host conference call and live webcast at 8:00 a.m. EDT todayCAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet medical need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced positive topline results...

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to report drill results from recent exploration drilling at the Valentine Gold Project, central Newfoundland (the “Project”). These latest results represent fire assay data from thirteen drill holes completed within the six-kilometre long Sprite Corridor, including the new Berry Zone. Highlights include:VL-20-838 intersected 1.47 g/t Au over 111 metres, including 35.02 g/t Au over 1 metre and including 14.92 g/t Au over 2 metres;VL-20-839 intersected 14.39 g/t Au over 9 metres, including 60.13 g/t Au over 2 metres, and 4.25 g/t Au over 15 metres, including 13.34 g/t Au over 4 metres;VL-20-837 intersected 8.24 g/t Au over 5 metres, including 36.21 g/t Au over 1 metre; andVL-20-844 intersected 4.38 g/t Au over 8...

The Company’s National Roll-Out of Tauri-Gum™ Targets Many Thousands of Retail Locations in More Than 30 U.S. StatesNew York, NY, Sept. 08, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE —  Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today commenced its long awaited national launch of its flagship brand – Tauri-Gum™.  Comprised of six distinct flavors, Tauri-Gum™ is a fast growing, technologically advanced product line that delivers Cannabidiol (“CBD”) and Cannabigerol (“CBG”) – as a Supplement – to customers, in the form of a proprietary chewing gum...

TORONTO, Sept. 08, 2020 (GLOBE NEWSWIRE) — Cardinal Resources Limited (ASX / TSX: CDV) (“Cardinal” or “the Company”) refers to its announcements of 2 and 3 September 2020 in relation to the revised Nord Gold S.E. (“Nordgold”) on-market takeover offer for Cardinal at A$0.90 cash per share (“Nordgold Takeover Bid”).As announced earlier today, Cardinal has received a revised and improved proposal for an off-market takeover offer from Shandong Gold Mining (HongKong) Co., Ltd. (“Shandong Gold”), pursuant to which Shandong Gold will offer to acquire all of the shares in Cardinal it does not presently own at a cash price of A$1.00 per share (“Improved Shandong Gold Offer”).The Cardinal Board, together with the Special Committee and its financial and legal advisers, carefully considered the Improved Shandong Gold Offer in detail and given...